Press release
United States Multi Cancer Early Detection Testing Market to hit US$ 3.06 Billion by 2033, Driven by Increasing Demand for Early Cancer Diagnosis and Advancements in Liquid Biopsy Technologies
Multi Cancer Early Detection Testing Market size
Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market?prasad
Multi Cancer Early Detection Testing Market Major Players:
GRAIL
GRAIL is a leading biotechnology company focused on multi-cancer early detection (MCED) testing using advanced liquid biopsy and genomic sequencing technologies. In 2025, GRAIL reported revenue of USD 0.6 billion, driven by adoption of its Galleri blood test in clinical and screening programs. In the multi-cancer early detection testing market, GRAIL plays a major role by using next-generation sequencing and machine learning to detect cancer signals from a single blood sample, enabling earlier diagnosis across multiple cancer types before symptoms appear.
Guardant Health, Inc.
Guardant Health is a leading precision oncology company specializing in liquid biopsy-based cancer diagnostics and monitoring. In 2025, the company reported revenue of USD 0.7 billion, driven by strong demand for its Guardant360 and Shield platforms. In the multi-cancer early detection testing market, Guardant Health plays a key role by developing blood-based genomic tests that detect circulating tumor DNA (ctDNA) for early cancer detection and recurrence monitoring. Its AI-driven analytics and sequencing technologies are widely used in oncology screening and personalized treatment planning.
Exact Sciences Corporation
Exact Sciences is a global leader in cancer screening and diagnostic testing, best known for its non-invasive colorectal cancer test Cologuard. In 2025, the company reported revenue of USD 2.7 billion, driven by expanding adoption of early cancer screening solutions. In the multi-cancer early detection testing market, Exact Sciences plays a significant role by developing blood-based and molecular diagnostic technologies aimed at detecting multiple cancers at early stages. Its pipeline includes advanced MCED solutions designed to improve survival outcomes through earlier intervention and broader population screening.
Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/multi-cancer-early-detection-testing-market?prasad
United States: Recent Industry Developments
✅ In March 2026, GRAIL, Inc. expanded multi-cancer early detection testing using liquid biopsy technologies. The innovation improves early diagnosis rates. GRAIL continues advancing cancer screening solutions.
✅ In February 2026, Guardant Health enhanced blood-based cancer detection tests for multiple cancer types. The development improves screening accuracy. Guardant continues strengthening oncology diagnostics.
✅ In January 2026, Exact Sciences Corporation expanded early cancer detection platforms with genomic analysis. The initiative improves patient outcomes. Exact Sciences continues advancing diagnostics innovation.
✅ In December 2025, Illumina, Inc. enhanced sequencing technologies supporting multi-cancer detection. The development improves testing capabilities. Illumina continues strengthening genomics leadership.
Japan: Recent Industry Developments
✅ In March 2026, Fujifilm Corporation expanded cancer screening technologies using AI and genomic analysis. The innovation improves early detection accuracy. Fujifilm continues advancing healthcare diagnostics.
✅ In February 2026, Sysmex Corporation enhanced liquid biopsy solutions for early cancer detection. The development improves diagnostic efficiency. Sysmex continues strengthening oncology testing.
✅ In January 2026, Hitachi, Ltd. expanded genomic analytics platforms for cancer screening applications. The initiative improves data-driven diagnosis. Hitachi continues advancing healthcare IT.
✅ In December 2025, Takeda Pharmaceutical Company enhanced collaborations in early cancer detection technologies. The development supports precision medicine. Takeda continues strengthening oncology innovation.
Segment Covered in the Multi Cancer Early Detection Testing Market:
By Test Type: Galleri Test
The Galleri test dominates the multi-cancer early detection (MCED) testing market due to its strong commercial presence and ability to screen for multiple cancer types using a single blood sample. It leverages circulating tumor DNA (ctDNA) to detect early-stage cancers across more than 50 cancer types, making it one of the most widely adopted MCED solutions globally.
This segment accounts for approximately 44% of the total market. Based on a global market size assumption of USD 1.8 billion in 2025, this translates to an estimated segment value of USD 792 million. Growth is driven by increasing adoption of liquid biopsy technologies, expanding clinical validation studies, and rising demand for early cancer detection solutions.
By Cancer Type: Breast Cancer
Breast cancer dominates the application landscape due to its high global prevalence and strong focus on early detection programs. MCED tests are increasingly used to complement existing screening methods such as mammography, improving detection across multiple cancer biomarkers.
This segment accounts for approximately 23% of the total market. Based on the USD 1.8 billion global market size in 2025, this corresponds to an estimated value of USD 414 million. Growth is driven by rising incidence rates, expanding screening awareness, and strong government-backed early detection initiatives.
By End User: Hospitals & Clinics
Hospitals and clinics lead the end-user segment as they are primary centers for cancer screening, diagnosis, and follow-up care. These institutions are increasingly integrating MCED tests into oncology workflows and preventive healthcare programs.
This segment accounts for approximately 49% of the total market. Based on the USD 1.8 billion global market size in 2025, this translates to an estimated value of USD 882 million. Growth is driven by increasing patient inflow for cancer screening, adoption of advanced diagnostic tools, and integration of precision medicine approaches.
Market Segmentation
The Multi Cancer Early Detection Testing Market is segmented by test type into Galleri Test, CancerSEEK, and others; by cancer type into breast cancer, colorectal cancer, lung cancer, blood cancer, prostate cancer, and others; by end user into hospitals & clinics, diagnostic laboratories, and academic & research institutes; and by region into North America, Europe, and Asia-Pacific.
Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/multi-cancer-early-detection-testing-market?prasad
Regional Analysis
North America
North America is the leading market due to advanced healthcare infrastructure, strong biotechnology ecosystem, and early adoption of liquid biopsy-based cancer screening technologies. The region is led by the United States.
The North American market is estimated at approximately USD 810 million in 2025, accounting for about 45% of the global market. Growth is driven by strong clinical adoption of MCED tests like Galleri, increasing R&D investments, and supportive healthcare innovation programs.
Europe
Europe is a significant market supported by strong public healthcare systems, rising cancer awareness, and increasing adoption of early diagnostic technologies. Key contributors include Germany, France, and the United Kingdom.
The European market is valued at approximately USD 630 million in 2025, representing about 35% of the global market. Growth is driven by government-backed cancer screening initiatives, improving diagnostic infrastructure, and increasing clinical validation of MCED technologies.
Asia-Pacific
Asia-Pacific is an emerging but rapidly growing market driven by rising cancer incidence, improving healthcare infrastructure, and increasing adoption of advanced diagnostic tools. Major contributors include China, India, and Japan.
The region is estimated at approximately USD 360 million in 2025, accounting for about 20% of the global market. Growth is supported by expanding screening awareness programs, increasing healthcare investments, and growing accessibility to advanced diagnostics.
Data-Driven Research Methodology for the Multi Cancer Early Detection Testing Market:
Our research process for the Multi Cancer Early Detection Testing Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.
Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=multi-cancer-early-detection-testing-market?prasad
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com
About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Multi Cancer Early Detection Testing Market to hit US$ 3.06 Billion by 2033, Driven by Increasing Demand for Early Cancer Diagnosis and Advancements in Liquid Biopsy Technologies here
News-ID: 4499835 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Secondary Battery Market to hit US$ 79.90 Billion by 2033, Driven …
The global Secondary Battery Market reached US$ 132.80 billion in 2025 and is expected to reach US$ 266.36 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2026-2033. Growth is driven by the rising adoption of electric vehicles and hybrid electric vehicles worldwide. Increasing demand for energy storage systems in renewable energy integration is further accelerating market expansion. The growing use of portable electronics and consumer…
United States Whole Genome Sequencing Market to hit US$ 5.49 Billion by 2033, Dr …
The Global Whole Genome Sequencing market reached US$ 2.45 billion in 2025 and is expected to reach US$ 18.3 billion by 2033, growing at a CAGR of 21.8% during the forecast period 2026-2033. Growth is driven by increasing demand for precision medicine and advanced genetic research. Rising adoption of genome sequencing in cancer diagnostics, rare disease detection, and personalized healthcare is accelerating market expansion. The declining cost of sequencing technologies…
Automotive Lead Acid Batteries Market Growth Drivers (2026-2033) | SLI Batteries …
DataM Intelligence has released a new research report titled "Automotive Lead Acid Batteries Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size…
United States Decentralized Edge Cloud Market to hit US$ 2.83 Billion by 2033, D …
The Global Decentralized Edge Cloud Market reached US$ 1.89 billion in 2025 and is expected to reach US$ 9.44 billion by 2033, growing with a CAGR of 19.55% during the forecast period 2026-2033. Growth is driven by increasing demand for low-latency data processing and real-time analytics applications. Rising adoption of IoT devices, 5G networks, and connected technologies is accelerating market expansion. The growing need for efficient distributed computing infrastructure is…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
